Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: The role of compartment and CD4-nadir

AIDS

Volumn 24, Issue 15, 2010, Pages 2347-2354

  Gutmann, Christine ^a   Cusini, Alexia ^b   Günthard, Huldrych F ^b   Fux, Christoph ^c   Hirschel, Bernard ^d   Decosterd, Laurent Arthur ^e   Cavassini, Matthias ^e   Yerly, Sabine ^f   Vernazza, Pietro L ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

central nervous system; genital tract; HIV; lopinavir; monotherapy

Indexed keywords

ABACAVIR; ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; RITONAVIR; RNA; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; ATAXIA; BLOOD; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CLINICAL TRIAL; CONCENTRATION LOSS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FEMALE; GENITAL SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEUROLOGIC DISEASE; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIALOADENITIS; TREATMENT FAILURE; TREATMENT RESPONSE; VIRUS LOAD; VISUAL DISORDER;

ADULT; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PYRIMIDINONES; RITONAVIR; RNA, VIRAL; SEMEN; TIME FACTORS; TREATMENT FAILURE; VIRAL LOAD;

EID: 77957231616     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833db9a1     Document Type: Article

References (21)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1 2009; 1-161. http://www.aidsinfo.nih. gov/ContentFiles/AdultandAdolescentGL.pdf. [Accessed 13 January 2010] (2009).auf http://www.aidsinfo.nih.gov/content files/adultandadolescentgl.pdf.
2. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4R T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512-517. (Pubitemid 29220209)
3. Umeh OC, Currier JS. Lipids, metabolic syndrome, and risk factors for future cardiovascular disease among HIV-infected patients. Curr HIV/AIDS Rep 2005; 2:132-139.
4. Havlir DV, Marschner IC, Hirsch MS, Collier AC, Tebas P, Bassett RL, et al. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med 1998; 339:1261-1268.
5. Arribas JR, Pulido F, Delgado R, Lorenzo A, Miralles P, Arranz A, et al. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr 2005; 40:280-287. (Pubitemid 41533067)
6. Vernazza P, Daneel S, Schiffer V, Decosterd L, Fierz W, Klimkait T, et al. The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial. AIDS 2007; 21:1309-1315. (Pubitemid 46883485)
7. Kovacs A, Wasserman SS, Burns D, Wright DJ, Cohn J, Landay A, et al. Determinants of HIV-1 shedding in the genital tract of women. Lancet 2001; 358:1593-1601. (Pubitemid 33101909)
8. Yerly S, Rutschmann OT, Opravil M, Marchal F, Hirschel B, Perrin L. Cell-associated HIV-1 RNA in blood as indicator of virus load in lymph nodes. The Swiss HIV Cohort Study. J Infect Dis 1999; 180:850-853.
9. Yerly S, Perneger TV, Vora S, Hirschel B, Perrin L. Decay of cellassociated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection. AIDS 2000; 14:2805-2812. (Pubitemid 32042743)
10. Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 1999; 354:729-733. (Pubitemid 29407396)
11. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1. Top HIV Med 2008; 16:138-145.
12. Arribas JR, Delgado R, Arranz A, Mun?oz R, Portilla J, Pasquau J, et al. Lopinavir-ritonavir monotherapy versus lopinavirritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr 2009; 51:147-152.
13. Kahlert C, Hupfer M, Wagels T, Bueche D, Fierz W, Walker UA, Vernazza PL. Ritonavir boosted indinavir treatment as a simplified maintenance?mono?-therapy for HIV infection. AIDS 2004; 18:955-957. (Pubitemid 38553720)
14. Swindells S, DiRienzo AG, Wilkin T, Fletcher CV, Margolis DM, Thal GD, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA 2006; 296:806-814. (Pubitemid 44223104)
15. Pulido F, Arribas JR, Delgado R, Cabrero E, González-García J, Pérez-Elias MJ, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS 2008; 22:F1-F9.
16. Hanson KE, Reckleff J, Hicks L, Castellano C, Hicks CB. Unsuspected HIV infection in patients presenting with acute meningitis. Clin Infect Dis 2008; 47:433-434. (Pubitemid 352009374)
17. Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009; 23:1359-1366.
18. Yeh R, Letendre S, Novak I, Lipman BA, Hermes A, Mayberry C. Single-agent therapy with lopinavir/ritonavir controls HIV-1 viral replication in the central nervous system. 14th Conference on Retroviruses and Oppotunistic Infections; Los Angeles, USA Abstract 381 (2007).
19. Ghosn J, Chaix ML, Peytavin G, Bresson JL, Galimand J, Girard PM, et al. Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine. J Antimicrob Chemother 2008; 61:1344-1347. (Pubitemid 351753606)
20. Kempf DJ, King MS, Bernstein B, Cernohous P, Bauer E, Moseley J, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004; 189:51-60. (Pubitemid 38122329)
21. Pulido F, Pérez-Valero I, Delgado R, Arranz A, Pasquau J, Portilla J, et al. Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. Antivir Ther (Lond) 2009; 14:195-201.